Kairos Pharma (KAPA) Fundamental Analysis: Revenue, Earnings & Valuation

8.75 / 10

Outperform

Fundamental analysis rates KAPA as Outperform with an 8.8/10 rating. Key strengths include high interest coverage, robust revenue growth, efficient inventory turnover, and favorable PB‑ROE. Weaknesses are high current‑liabilities ratio, long‑term debt relative to working capital, and low asset‑MV.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight82.64%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight1.13%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-9.42%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight-34.92%

1M Return-4.96%

PB-ROE

Value0.92

Score2/3

Weight77.08%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value26.96

Score0/3

Weight-35.90%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-9.58%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.46%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-9.05%

1M Return-1.13%

Asset-MV

Value-0.49

Score0/3

Weight37.56%

1M Return4.00%

Is KAPA undervalued or overvalued?

KAPA scores 8.75/10 on fundamentals and holds a Discounted valuation at present. Backed by its -97.99% ROE, 0.00% net margin, -2.28 P/E ratio, 1.96 P/B ratio, and -30.43% earnings growth, these metrics solidify its Outperform investment rating.